The Use of Low-Dose Recombinant Tissue Plasminogen Activator to Treat a Preterm Infant with an Intrauterine Spontaneous Arterial Thromboembolism

Turk J Haematol. 2015 Dec;32(4):359-62. doi: 10.4274/tjh.2015.0016. Epub 2015 Aug 6.

Abstract

Neonatal thromboembolic events are rare, and only a few cases of intrauterine spontaneous arterial thromboembolisms have been reported in the literature. Thrombolytic therapy with recombinant tissue plasminogen activator is usually the preferred treatment because it has a short half-life, fewer systemic side effects, and a strong, specific affinity for fibrin. Protocols vary from center to center, but there is still no consensus regarding the proper dosage or treatment duration. Herein, we present the case of an intrauterine spontaneous arterial thromboembolism in a preterm infant that completely resolved after being treated with low-dose recombinant tissue plasminogen activator (0.02 mg/kg/h).

Yenidoğanda tromboembolik olaylar sık değildir. Literatürde spontan intrauterin arteriyel tromboz olgusu oldukça az bildirilmiştir. Tromboemboli tedavisinde yarılanma ömrü kısa olduğu için rekombinan doku plazminojen aktivatörü çoğunlukla tercih edilmektedir. Tedavi protokolü merkezden merkeze değişiklik göstermesine karşın, doz ve süre konusunda bir uzlaşı yoktur. Biz burada kullanılabilecek en düşük dozlardan biriyle (0,02 mg/kg/doz) tamamen iyileşme sağladığımız intrauterin spontan arteriyel trombozlu bir olguyu sunmak istedik.

Publication types

  • Case Reports

MeSH terms

  • Arterial Occlusive Diseases / congenital
  • Arterial Occlusive Diseases / drug therapy*
  • Brachial Artery*
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Enoxaparin / therapeutic use
  • Fibrinolytic Agents / administration & dosage
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Infant, Premature, Diseases / drug therapy*
  • Male
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / therapeutic use
  • Thromboembolism / drug therapy*
  • Thrombolytic Therapy / methods*
  • Tissue Plasminogen Activator / administration & dosage
  • Tissue Plasminogen Activator / therapeutic use*

Substances

  • Enoxaparin
  • Fibrinolytic Agents
  • Recombinant Proteins
  • Tissue Plasminogen Activator